Phase II clinical trial - Phases précoces tumeurs solides

Efficacy of immunotherapy in combination with a drug in patients with;advanced mucosal cancer of different locations that has progress.Patients will be treated until disease progression (or for up to 35 cycles for pembrolizumab) or;unacceptable toxicity or patient decision.;Continuation of pembrolizumab beyond 35 cycles may be allowed under certain conditions and;must be agreed with the sponsor before continuing the treatment.